Advertisement

Medicinal Chemistry Research

, Volume 23, Issue 11, pp 4642–4656 | Cite as

1,4-Dioxolane-triazaspirodecanone derivatives as nociceptin/orphanin FQ receptor ligands

  • Sandra Corrado
  • Claudia Sorbi
  • Annalisa Tait
  • Umberto M. Battisti
  • Valeria Camarda
  • Davide Malfacini
  • Girolamo Calò
  • Livio Brasili
Original Research

Abstract

A series of N-substituted analogs based upon the spiropiperidine core of the lead compound Spiroxatrine was synthesized. In particular, the new compounds were obtained by replacing the benzodioxane moiety of the Spiroxatrine with several 2-substituted 1,3-dioxolanes. Thus the designed derivatives were synthesized and evaluated as possible NOP receptor ligands. As a conclusion of these studies, the new triazaspirodecanone derivatives showed unique and significant SAR as NOP receptor agonists. In particular, the present study demonstrated that 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one portion together with appropriate 1,3-dioxolane substituents could lead to a new promising class of NOP receptor ligands.

Keywords

NOP receptors Spiroxatrine derivatives Triazaspirodecanones 

References

  1. Ambo A, Hamazaki N, Yamada Y, Nakata E, Sasaki Y (2001) Structure–activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides. J Med Chem 44:4015–4018CrossRefPubMedGoogle Scholar
  2. Andoh T, Yaqeta Y, Takeshima H, Kuraishi YI (2004) Intradermal nociceptin elicits itch-associated responses through leukotriene B-4 in mice. J Invest Dermatol 123:196–201CrossRefPubMedGoogle Scholar
  3. Brasili L, Sorbi C, Franchini S, Manicardi M, Angeli P, Marucci G, Leonardi A, Poggesi E (2003) 1,3-dioxolane-based ligands as a novel class of α 1-adrenoceptor antagonists. J Med Chem 46:1504–1511CrossRefPubMedGoogle Scholar
  4. Calò G, Guerrini R, Bigoni R (1998) Structure–activity study of the nociceptin(1–13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med Chem 41:3360–3366CrossRefPubMedGoogle Scholar
  5. Camarda V, Fischetti C, Anzellotti N, Molinari P, Ambrosio C, Kostenis E, Regoli D, Trapella C, Guerrini R, Salvadori S, Calò G (2009) Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha(qi5). Naunyn Schmiedebergs Arch Pharmacol 379:599–610CrossRefPubMedGoogle Scholar
  6. Chen Y, Fan Y, Liu J, Mestek A, Tian M, Kozak CA, Yu L (1994) Molecular-cloning, tissue distribution and chromosomal localization of novel member of the opioid receptor gene family. FEBS Lett 347:279–283CrossRefPubMedGoogle Scholar
  7. Fischetti C, Camarda V, Rizzi A, Pelà M, Trapella C, Guerrini R, McDonald J, Lambert DG, Salvadori S, Regoli D, Calò G (2009) Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. Eur J Pharmacol 614:50–57CrossRefPubMedGoogle Scholar
  8. Granata F, Potenza RL, Fiori A, Strom R, Caronti B, Molinari P, Donsante S, Citro G, Iacovelli L, de Blasi A (2003) Expression of OP4 (ORL1, NOP1) receptors in vascular endothelium. Eur J Pharmacol 482:1–3CrossRefGoogle Scholar
  9. Guerrini R, Calò G, Bigoni R, Rizzi D, Rizzi A, Zucchini M, Varani K, Hashiba E, Lambert DG, Toth G (2001) Structure-activity studies of the Phe4 residue of nociceptin(1–13)-NH2: identification of highly potent agonists of the nociceptin/orphanin FQ receptor. J Med Chem 44:3956–3964CrossRefPubMedGoogle Scholar
  10. Jacoby E, Bouhelal R, Gerspacher M, Seuwen K (2006) The 7TM G-protein-coupled receptor target family. ChemMedChem 1:761–782CrossRefPubMedGoogle Scholar
  11. Kawamoto H, Ozaki S, Itoh Y, Miyaji M, Arai S, Nakashima H, Kato T, Ohta H, Iwasawa Y (1999) Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl- 1,3-dihydro-2H-benzimidazol-2-one (J-113397). J Med Chem 42:5061–5063CrossRefPubMedGoogle Scholar
  12. Lambert DG (2008) The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov 7:694–710CrossRefPubMedGoogle Scholar
  13. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvineria P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B, Mazargull H, Vassart G, Parmentier M, Costantin J (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532–535CrossRefPubMedGoogle Scholar
  14. Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, Caput D, Vassart G, Meunier C (1994) ORL1, a novel member of the opioid receptor family: cloning, functional expression and localization. FEBS Lett 341:33–38CrossRefPubMedGoogle Scholar
  15. Mollereau C, Mouledous L (2000) Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 21:907–917CrossRefPubMedGoogle Scholar
  16. Mustazza C, Bastanzio G (2011) Development of nociceptin receptor (NOP) agonists and antagonists. Med Res Rev 31:605–648CrossRefPubMedGoogle Scholar
  17. Okada K, Sujaku T, Chuman Y, Nakashima R, Nose T, Costa T, Yamada Y, Yokoyama M, Nagahisa A, Shimohigashi Y (2000) Highly potent nociceptin analog containing the Arg-Lys triple repeat. Biochem Biophys Res Commun 278:493–498CrossRefPubMedGoogle Scholar
  18. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Gandy K, Langen H, Monsma FJ, Civelli O (1995) Orphanin FQ: a neuropeptide that activates an opioid like G protein-coupled receptor. Science 270:792–794CrossRefPubMedGoogle Scholar
  19. Sorbi C, Franchini S, Tait A, Prandi A, Gallesi R, Angeli P, Marucci G, Pirona L, Poggesi E, Brasili L (2009) 1,3-dioxolane-based ligands as rigid analogues of naftopidil: structure-affinity/activity relationships at alpha(1) and 5-HT1A receptors. ChemMedChem 4:393–399CrossRefPubMedGoogle Scholar
  20. Thomsen C, Hohlweg R (2000) (8-naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]-dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist. Br J Pharmacol 131:903–908PubMedCentralCrossRefPubMedGoogle Scholar
  21. Zaveri N (2003) Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci 73:663–678PubMedCentralCrossRefPubMedGoogle Scholar
  22. Zhang C, Miller W, Valenzano KJ, Kyle DJ (2002) Novel, potent ORL-1 receptor agonist peptides containing α-Helix-promoting conformational constraints. J Med Chem 45:5280–5286CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Sandra Corrado
    • 1
  • Claudia Sorbi
    • 1
  • Annalisa Tait
    • 1
  • Umberto M. Battisti
    • 1
  • Valeria Camarda
    • 2
  • Davide Malfacini
    • 2
  • Girolamo Calò
    • 2
  • Livio Brasili
    • 1
  1. 1.Department of Life SciencesUniversity of Modena and Reggio EmiliaModenaItaly
  2. 2.Department of Medical Sciences, Section of Pharmacology and National Institute of NeuroscienceUniversity of FerraraFerraraItaly

Personalised recommendations